563P - Is triple negative breast cancer really bad? 10 year audit from a tertiary center
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Pathology/Molecular Biology
|Presenter||Prameela Chelakkot G|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix181-ix183. 10.1093/annonc/mdw602|
P. Chelakkot G1, R. Ravind2, S. K3, W.M. Jose4
Incidence of triple negative breast cancer (TNBC) is 15%-20%, and has relatively poor prognosis, attributed to absence of a definitive target molecule. Chemotherapy and adjuvant radiation remains the standard-of-care. Audit of all cases of TNBC treated at our tertiary cancer care centre was done with intent to analyze the pattern of failure.
Details of all TNBC patients, treated from January, 2004 to June, 2015 were retrieved from the electronic medical records and were analyzed.
A total of 276 TNBC patients were treated in this 10 year period. Median age of presentation was 50 (range: 25-81). Median follow-up was 37.03 months. 96.4% of patients had infiltrating duct carcinoma. MRM was offered for 67.4% and BCS for 29.7%. 92% had axillary dissection. Upfront chemotherapy was offered for 18.8%, and adjuvant chemotherapy for 77.2%. 49.6% received adjuvant radiation. Fifty (18.1%) patients had recurrence; 4 local (1.4%), 3 regional (1.1%) and 40 distant (14.5%). Three patients had regional and distant failures. Among the 40 distant metastasis, 12 were brain, 8 skeletal, 4 hepatic, 2 pulmonary and 18 had multi-site. 144 (52.2%) patients were alive with no disease. 5-year OS was 88.03%. Stage was the only significant factor affecting OS. Stage I had 100% 5 year OS, stage II 95.5%, stage III 82.2% and stage IV 53.3% (p-
Contrary to western literature our TNBC patients had better survival: 3-year OS 74% vs. 90.08%. Failure in TNBC is generally systemic and is approximately 4 times more than loco-regional failures. Irrespective of nodal status T4 lesions fared poorly. Patients with BCS had less failures compared to MRM, probably due to early disease and addition of adjuvant radiation.
Clinical trial indentification
This was a retrospective analysis and an audit of all Triple Negative Breast cancer cases who had presented to the institue in the 10 year period. This was not a study protocol.
Legal entity responsible for the study
All authors have declared no conflicts of interest.